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Abstract 
Calcium channel blockers, which alter the intracellular calcium concentration by modifying calcium flux 
across cell membranes and affect various intracellular signaling processes, have been long and widely used 
to treat essential hypertension and certain types of cardiac diseases such as angina pectoris. Among five 
subtypes of calcium channels, only specific agents for L-type calcium channels have been used as 
therapeutics. There are potentially multiple biological bases for the protective effect of calcium channel 
blockers on eye structures. The objective of this review is to evaluate the evidence and discuss the rationale 
behind the recent suggestions that calcium channel blockers may be useful in the prevention and the 
treatment of different eye diseases.      
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1. Introduction 
Calcium channel blockers, which alter the intracellular calcium concentration by modifying calcium flux 
across cell membranes and affect various intracellular signaling processes, have been long and widely used 
to treat essential hypertension and certain types of cardiac diseases such as angina pectoris (Nelson, 2010).  
Among five subtypes of calcium channels, only specific agents for L-type calcium channels have been used 
as therapeutics. Calcium antagonists induce vasodilatation at smooth muscle cells and are neuroprotective 
through their intracellular decrease of K +. 
Calcium channel blockers generally dilate isolated ocular vessels and increase ocular blood flow in 
experimental animals, healthy humans, patients with open-angle glaucoma (Luksh et al., 2005; Koseki et al., 
2008; Araie and Yamaya, 2011) and in patients who have vascular diseases in which considerable vascular 
tone is present. As well, contrast sensitivity in patients with normal tension glaucoma was found 
ameliorated by calcium channel inhibition (Yu et al., 1999; Boehm et al., 2003). Neuroprotective effect of 
calcium channel blockers against retinal ganglion cell damage under hypoxia was shown by Yamada et al. 
(2006), and also by Garcia-Campos et al. (2007). 
Apoptosis, genetically programmed mechanism of cell death in which the cell activates a specific set of 
instructions that lead to the deconstruction of the cell from within, is now understood as a final common 
pathway for retinitis pigmentosa. Retinitis pigmentosa is an inherited retinal degeneration characterized by 
nyctalopia, ring scotoma, and bone-spicule pigmentation of the retina. Apoptosis can thus be considered as 
a therapeutic target for retinitis pigmentosa (Doonan and Gotter, (2004); Cottet and Schorderet, (2009)). 
The general consensus is that intracellular concentrations of calcium ion are increased in apoptosis 
(Nicotera and Orrenius, 1998; Fox et al., 1999; Delyfer et al., 2004; Sanges et al., 2006; Paquet-Durand et 
al., 2007 Sasati and Kaneko, 2007).  
These findings suggest that calcium channel blockers may potentially inhibit ganglion cells and 
photoreceptor apoptosis in glaucoma and retinitis pigmentosa respectively (Araiet and Yamaya, 2011; 
Nakazawa, 2011), and furthermore apoptosis can thus be considered as a therapeutic target. 
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There are potentially multiple biological bases for the protective effect of calcium channel blockers on eye 
structures, as was shown above. 
The objective of this review is to evaluate the evidence and discuss the rationale behind the recent 
suggestions that calcium channel blockers may be useful in the prevention and the treatment of different 
eye diseases. 
2. Eye Diseases 
2.1 Glaucoma 
Glaucoma is a major cause of worldwide irreversible blindness. Bilateral blindness will be present in 5.9 
million people with open-angle glaucoma and 5.3 million people with angle-closure glaucoma in 2020. 
Currently, glaucoma is recognised as an optic neuropathy and the loss of vision in this eye disease is 
attributed to degeneration of the axons of the retinal ganglion cells through apoptosis. 
2.2 Retinitis pigmentosa 
Retinitis pigmentosa (RP) represents a group of progressive hereditary diseases of the retina that lead to 
incurable blindness and affect two million people worldwide; RP has been known to be initiated by 
photoreceptor apoptosis as a final common pathway at the cellular level, irrespective of gene mutations. 
2.3 Cataract 
Cataract is a main cause of treatable blindness due to opacification of the lens. 
3. Calcium Channel Blockers 
3.1 Nifedipine 
Nifedipine is a dihydropyridine calcium channel blocker. Its main uses are as an antianginal (especially in 
Prinzmetal's angina) and antihypertensive. Yamazaki et al., (2002) evaluated the pharmacologic effects of 
several Calcium channel blockers, including nifedipine on the retinal degeneration of Royal College of 
Surgeons (RCS) rat, which is the most extensively studied animal model for understanding the molecular 
pathology in inherited retinal degeneration, such as retinitis pigmentosa. The authors concluded that 
nifedipine is not beneficial for the preservation of photoreceptor cells in RCS rats. Furthermore Takano et 
al., (2004) also recognized that nifedipine is not able to preserve photoreceptor cells in rod ( rd ) mouse and 
cannot be used to treat patients with retinitis pigmetnosa. Otori et al., (2003) in the experimental study of 
calcium channel blockers protective effect against glutamate neurotoxicity in purified retinal ganglion cells 
has found that nifedipine does not inhibit glutamate-induced apoptotic cell death. Moreover  Harris et al., 
(1997) investigated in observational study ocular hemodynamic and visual function changes in patients 
with normal-tension glaucoma after treatment with nifedipine during 6 months (30mg per day). Mean 
intraocular pressure, retrobulbar hemodynamics, visual field mean sensitivity were unchanged after 
treatment, however contrast sensitivity was improved. The authors concluded that nifedipine fails to 
provide uniform visual function or retrobulbar hemodynamics responses in patients with normal –tension 
glaucoma, but those patients who do show improved visual function also show improved indices of 
retrobulbar perfusion. The limitation of this study includes small sample size without control group. 
3.2 Verapamil 
Verapamil (phenylalkylamine class), is relatively selective for the myocardium, and is less effective as a 
systemic vasodilator drug. This drug has a very important role in treating angina (by reducing myocardial 
oxygen demand and reversing coronary vasospasm) and arrhythmias. Ettl et al., (2004) investigated the 
efficacy of verapamil eye drops for inhibition of diabetic cataract in rats. The authors stated that Verapamil 
eye drops 0.2% administered three times daily are effective in inhibiting the progression of lens opacities in 
streptozotocin diabetic rats. These encouraging findings need to be confirmed by further studies.      
Furthermore  Siegner et al., (2000) have evaluated the impact of calcium channel blockers on intraocular 
pressure in the primate eye and found that topical application of all classes of calcium channel blockers, 
especially verapamil, caused significant intraocular pressure reductions, while ocular hypotensive effects in 
humans were not substantial (Araie and Mayama, 2011). In addition combination of verapamil with 
antiglaucoma medications may provide a useful alternative for reducing intraocular pressure in patients 
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with primary open-angle glaucoma. 
3.3 Diltiazem 
Diltiazem (benzothiazepine class) is intermediate between verapamil and dihydropyridines in its selectivity 
for vascular calcium channels. By having both cardiac depressant and vasodilator actions, diltiazem is able 
to reduce arterial pressure without producing the same degree of reflex cardiac stimulation caused by 
dihydropyridines. Frasson et al., (1999) first reported the  effects of D-cis- diltiazem, a benzothiazepin 
calcium channel antagonist which blocks both cyclic-nucleotid-gated cation channels (CNGC) and 
voltage-gated calcium channels (VGCC) on photoreceptor protection in rd1 mice,  moreover several 
investigators have reported positive and negative effects of calcium channel blockers on animal models  of 
retinitis pigmentosa (Bush et al., 2000; Pearce-Kelling et al., 2001; Yamazaki et al., 2002; Hart et al., 2003; 
Sato et al., 2003; Takano et al., 2004; Vallazza-Deschamps et al., 2005; Sanges et al., 2006; Takeuchi et al., 
2008). The intracellular concentration of calcium ions is subsequently elevated, leading to photoreceptor 
apoptosis (Frasson et al., 1999).  In addition Sanges et al. (2006) demonstrated that systemic 
administration of D-cis-diltiazem reduced intracellular concentrations of calcium, downregulating calpains 
and photoreceptor apoptosis in rd1 mice.  Furthermore direct inhibitory effects of D-cis-diltiazem on 
L-type VGCC have been reported by Hart et al. (2003), and D-cis-diltiazem effectively blocks 
photoreceptor light damage in mouse models by inhibiting photoreceptor apoptosis (Valazza-Deschamps et 
al., 2005). In contrast, L-cis isomer inhibits L-type VGCC similarly to D-cis isomer (Cia et al., 2005). 
The difference in action between D-cis and L-cis-diltiazem on photoreceptor apoptosis suggests that CNGC 
might also be important for photoreceptor neuroprotection (Frasson et al., 1999). Despite these studies, 
however, Pawlyk et al.(2002) and Takano et al. (2004) found no rescue effects of D-cis-diltiazem on retinal 
degeneration in rd1 mice, and furthermore Bush et al. (2000) also reported that D-cis-diltiazem was 
ineffective for photoreceptor rescue in rhodopsim P23H transgenic rats. The effects of diltiazem on animal 
models of retinal degeneration remain controversial. 
In addition Pasantes-Morales et al. (2002) in human study reported that a combination of D-cis-diltiazem, 
taurin, and vitamin E has beneficial effects on the visual field progression, although the study did not 
clarify whether diltiazem alone demonstrated beneficial effects. Moreover Otori et al. (2003) evaluated the 
effect of diltiazem on inhibition of glutamate-induced apoptotic retinal ganglion cells death and concluded 
that application of diltiazem do not appear to reduce apoptosis. Investigating the pharmacokinetics of 
diltiazem after subconjunctival and topical administration in rabbits and effect on wound healing after the 
creation of conjunctival flaps, Oruc et al. (2000) have found that topical and subconjunctival diltiazem 
successfully penetrated the aqueous humor, but did not appear to affect wound healing. Furthermore based 
on antioxidative  action of calcium channel blockers, which have recently been shown, another therapeutic 
target is ocular inflammation. Animal study of intraperitoneal injections of either nilvadipine, diltiazem, or 
vehicle have not found a beneficial inhibitory effect of diltiazem on the pathogenesis of ocular 
inflammation through the suppression of inflammation-related molecules (Ishida et al., 2010). 
3.4 Nimodipine 
Nimodipine is an isopropyl calcium channel blocker which readily crosses the blood-brain barrier due to its 
high lipid solubility. Its primary action is to reduce the number of open calcium channels in cell membranes, 
thus restricting influx of calcium ions into cells. Several clinical trials have unequivocally shown that 
nimodipine is capable of preventing neurological deficits secondary to aneurysmal subarachnoid 
haemorrhage. The results of the VENUS (Very Early Nimodipine Use in Stroke) study do not support the 
concept that early nimodipine exerts a beneficial effect in stroke patients (Horn et al., 2001). On the other 
hand oral nimodipine showed an enhanced acute reperfusion if applied within 12 hours of onset of acute 
stroke (Infeld et al., 1999). Yamada et al., (2006) in experimental in vitro model revealed that nimodipine 
have a direct neuroprotective effect against retinal ganglion cells damage related to hypoxia. Furthermore  
Michelson et al., (2006) have evaluated the impact of nimodipine on retinal blood flow in double-blind, 
two-way, crossover study of healthy subjects and found that orally administered at a dosage of 30 mg three 
times a day nimodipine significantly increases retinal perfusion in healthy subjects. Based on experimental 
findings Shahsuvaryan (2008) investigated the efficacy of nimodipine in the prospective comparative 
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clinical interventional study of patients with nonarteritic anterior and posterior optic neuropathy. The author 
stated that increase in visual acuity was higher in the posterior ischemic neuropathy subgroup than in the 
anterior ischemic subgroup. Visual field testing during the follow-up also revealed positive transformation 
of visual field defects size and location, which correlated to visual acuity changes. These encouraging 
findings need to be confirmed by double-blind study. In addition Nimodipine has also been shown to 
significantly inhibit the growth of new vessels in experimental rat model of retinopathy of prematurity 
(Juarez et al., 2000). Vascular endothelial growth factor (VEGF) can induce cell proliferation by activating 
the calcium channel in cell membrane through the influx of calcium increased. Moreover another animal 
study (Kong et al., 2004) also have found a beneficial inhibitory effect of nimodipine on proliferative 
retinopathy by blocking the influx of calcium and expression of VEGF. The impact of nimodipine on ocular 
circulation in normal tension glaucoma has been evaluated in many clinical studies. 
Piltz et al., (1998) have described a performance-corrected improvement in visual field deviation and 
contrast sensitivity in patients with normal  tension glaucoma (NTG) and in control subjects in a 
prospective, placebo-controlled double-masked study after oral administration of nimodipine (30 mg twice  
a day). Furthermore other authors (Michalk et al., 2004) also stated that a single dose of 30mg nimodipine 
normalizes the significantly reduced retinal blood flow in NTG patients with clinical signs of vasospasmic 
hyperactivity. In addition Luksch et al., (2005) have examined the impact of 60 mg nimodipine in NTG 
patients 2 hours after oral administration. Results disclosed that nimodipine increased the blood flow of the 
optic nerve head by 18% and improved color-contrast sensitivity. Thus, nimodipine is potentially useful 
calcium channel blocker for eye disorders treatment due to its high lipid solubility and ability to cross the 
blood-brain barrier.  
3.5 Nilvadipine 
Recent experimental evidences suggest that Nilvadipine appear to have beneficial effects on different 
ocular structures. Ogata et al., (2000) have evaluated the effects of nilvadipine on retinal blood flow and 
concluded that this agent may directly and selectively increase retinal tissue blood flow, while having only 
minimal effect on systemic circulation including arterial blood pressure. Furthermore  another 
experimental study conducted by Uemura and Mizota (2008) have also advocated the use of nilvadipine for 
the treatment of glaucoma or other retinal diseases that have some relation to apoptosis, based on claims 
that nilvadipine has high permeability to retina and neuroprotective effect to retinal cells.  Moreover  
Otori et al., (2003) in the experimental study of different calcium channel blockers protective effect against 
glutamate neurotoxicity in purified retinal ganglion cells has found that nilvadipine significantly reduce 
glutamate-induced apoptosis. Furthermore systemic administration of nilvadipine has been shown to be 
effective for protecting photoreceptors in royal college surgeons rats (Yamazaki et al., 2002), rd1 mice 
(Takano et al., 2004), and heterozygous rd2 (rds) mice (Takeuchi et al., 2008). In addition to direct  effects 
of calcium channel blockers on intracellular concentrations of calcium ion in photoreceptor cells, other 
indirect effects are expected such as increased expression of fibroblast growth factor (FGF) 2 (Takano et al., 
2004) and ciliary neurotrophic factor (CNTF) in the retina (Takeuchi et al., 2008), and increased choroidal 
blood flow (Koseki et al., 2008). Furthermore in the latest animal study of intraperitoneal injections of 
nilvadipine Ishida et al., (2010) have found a beneficial inhibitory effect of this drug on the pathogenesis of 
ocular inflammation through the suppression of inflammation-related molecules. Several clinical trials have 
shown the effectiveness of nilvadipine in retinitis pigmentosa and glaucoma. Ohguro (2008) reported the 
photoreceptor rescue effects of nilvadipine in a small patient group.  Moreover Nakazawa et al., (2011) 
expanded his nilvadipine study for RP patients to confirm the results. Although both treated and control 
groups are still small, authors results have shown significant retardation of the mean deviation (MD) slope 
as calculated by the central visual field (Humphry Visual Field Analyzer, 10-2 Program) after a mean of 48 
months of observation. As these pilot studies are small-sized and cannot completely exclude possible biases, 
a large-scale, randomized, multicenter human trial of calcium channel blockers is required in order to 
evaluate their efficacy as therapeutic agents for retinitis pigmentosa. The potential beneficial impact of 
nilvadipine on ocular circulation in normal tension glaucoma has been evaluated in different clinical studies. 
Yamamoto et al., (1998), Tomita et al., (1999), Niwa et al., (2000) have found that nilvadipine reduces 
vascular resistance in distal retrobulbar arteries and significantly increases velocity in the central retinal 
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artery in patients with normal tension glaucoma. Furthermore Tomita et al., (1999) also stated that reduced 
orbital vascular resistance after a 4-week treatment with 2 mg oral nilvadipine consequently increases the 
optic disc blood flow. Moreover, Koseki et al., (2008) conducted a randomized, placebo-controlled, 
double-masked, single-center 3-year study of nilvadipine on visual field and ocular circulation in glaucoma 
with low-normal pressure. No topical ocular hypotensive drugs were prescribed. The authors concluded that 
nilvadipine (2 mg twice daily) slightly slowed the visual field progression and maintained the optic disc rim, 
and the posterior choroidal circulation increased over 3 years in patients with open-angle glaucoma with 
low –normal intraocular pressure. The results of this study add to the growing body of evidence that 
nilvadipine may be useful for neuroprotection in glaucoma. Thus, nilvadipine is potentially useful calcium 
channel blocker for eye disorders treatment due to its hydrophobic nature with high permeability to the 
central nervous system, including the retina and the highest antioxidant potency among calcium channel 
blockers. 
3.6 Other calcium channel blockers 
The experimental study conducted by Oku et al., (2000), evaluated the effect of topical iganidipine, a new 
dihydropyridine derivative calcium channel blocker on the impaired visual evoked potential after 
endothelin-1 injection into the vitreous body of rabbits and have advocated iganidipine eyedrops for the 
treatment of ischemic retinal and optic nerve disorders for the maintenance of visual function. Furthermore 
the latest experimental study (Karim et al., 2006) evaluated a neuroprotective effect of another new calcium 
channel blocker – lomerizine. The authors stated that lomerizine alleviates secondary degeneration of 
retinal ganglion cells induced by an optic nerve crush injury in the rat, presumably by improving the 
impaired axoplasmic flow.  In addition Tamaki et al., (2003) also investigated the effects of lomerizine on 
the ocular tissue circulation in rabbits and on the circulation in the optic nerve head and choroid in healthy 
volunteers and have found that lomerizine increases blood velocity, and probably blood flow, in the optic 
nerve head and retina in rabbits, and it also increases blood velocity in the optic nerve head in healthy 
humans, without significantly altering blood pressure or heart rate. 
4. Future implications 
Diabetic retinopathy (DR) remains the leading cause of blindness among working-age individuals in 
developed countries. The latest findings by Simo and Hernandez (2012) suggest that retinal 
neurodegeneration is an early event in the pathogenesis of diabetic retinopathy, which participates in the 
microcirculatory abnormalities that occur in DR. Therefore, the study of the underlying mechanisms that 
lead to neurodegeneration will be essential for identifying new therapeutic targets. From the clinical point 
of view, the identification of those patients in whom retinal neurodegeneration appears will be crucial for 
implementing early treatment based on neuroprotective drugs. We suppose to use neuroprotective effect of 
calcium channel blockers in this field also. 
5. Conclusion  
In conclusion, there are potentially multiple biological bases for the therapeutic effect of calcium channel 
blockers in eye diseases. Taken into account that not all calcium channel blockers are equally effective, the 
challenge for future laboratory research will be to determine the best type and dosage of calcium channel 
blockers and also to determine which processes are modulated by these drugs in vivo and therefore are 
primarily responsible for the apparent beneficial effects observed in the previous studies. Clearly, further 
observational studies cannot adequately address many unanswered questions. It is time to conduct a 
randomized controlled trial to provide direct evidence of the effectiveness of specific type calcium channel 
blocker in eye diseases. In author’s opinion we are standing at the beginning of the noninvasive 
pharmacotherapy of a major eye diseases by calcium channel blockers. 
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